MARKET

BLRX

BLRX

BioLine RX
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.668
-0.002
-0.09%
Opening 09:42 09/20 EDT
OPEN
2.620
PREV CLOSE
2.670
HIGH
2.668
LOW
2.610
VOLUME
79.65K
TURNOVER
--
52 WEEK HIGH
6.34
52 WEEK LOW
1.400
MARKET CAP
126.11M
P/E (TTM)
-2.1742
1D
5D
1M
3M
1Y
5Y
BioLineRx Plans American Depository Share Offering
MT Newswires · 09/03 17:01
BioLine Rx Q2 EPS $(0.01) Beats $(0.15) Estimate
BioLine Rx (NASDAQ:BLRX) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.15) by 93.33 percent. This is a 66.67 percent increase over losses of $(0.03) per share from the
Benzinga · 08/18 11:07
BioLineRx Reports Second Quarter 2021 Financial Results and Provides Corporate Update
/PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the quarter ended and provides a corporate update.
PR Newswire - PRF · 08/18 11:00
Earnings Scheduled For August 18, 2021
  Companies Reporting Before The Bell • Digital Ally (NASDAQ:DGLY) is likely to report quarterly loss at $0.04 per share on revenue of $2.70 million.
Benzinga · 08/18 09:34
Notable earnings before Wednesday's open
ADI,OTCPK:AWLCF,BLRX,DGLY,DQ,EAT,LITE,LOW,NNDM,PLCE,SFL,TGT,TJX,VIPS,WB,ZIM For Seeking Alpha's full earnings season calendar, click here.
Seekingalpha · 08/17 15:47
BioLineRx to Report Second Quarter 2021 Results on August 18, 2021
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended June 30, 2021 on Wednesday, August 18, 2021, before the U...
PR Newswire · 08/12 13:30
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Delcath Systems (NASDAQ:DCTH) stock increased by 8.87% to $11.9 during Friday's after-market session. This security traded at a volume of 379 shares come close, making up 0.45% of its average volume over the last 100 days. The company's market cap...
Benzinga · 07/09 21:20
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers
Benzinga · 07/06 20:31
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of BLRX. Analyze the recent business situations of BioLine RX through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average BLRX stock price target is 14.50 with a high estimate of 19.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 50
Institutional Holdings: 1.68M
% Owned: 3.56%
Shares Outstanding: 47.27M
TypeInstitutionsShares
Increased
2
306.92K
New
8
131.56K
Decreased
8
670.47K
Sold Out
6
3.16M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-1.98%
Pharmaceuticals & Medical Research
-1.22%
Key Executives
Chairman/Director
Aharon Schwartz
Chief Executive Officer
Philip Serlin
Chief Financial Officer
Mali Zeevi
Vice President
Ella Sorani
Chief Scientific Officer
Merril Gersten
Vice President
Moshe Phillip
Vice President
Abi Vainstein-Haras
Vice President - Business Development
Hillit Mannor Shachar
Vice President - Business Development
David Malek
Director
Michael Anghel
Director
Barbara-Jean Bormann
General Manager
Leah Klapper
Director
Raphael Hofstein
Director
Sandra Panem
Non-Executive Director
Nurit Benjamini
Director
Jacob Friedman
No Data
About BLRX
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

Webull offers kinds of BioLine RX Ltd stock information, including NASDAQ:BLRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BLRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BLRX stock methods without spending real money on the virtual paper trading platform.